Christopher Zerwas
About Christopher Zerwas
Christopher Zerwas serves as the Vice President of Sales at Variantyx, bringing extensive experience in genetic testing and sales management from his previous roles at GeneDx, Athena Diagnostics, and PerkinElmer Genomics.
Current Role at Variantyx
Christopher Zerwas serves as the Vice President of Sales at Variantyx, a position he has held since 2020. Based in Boston, Massachusetts, he focuses on driving sales strategies and expanding the company's market presence in the genetic testing sector. His role involves overseeing sales operations and collaborating with various teams to promote advanced genetic testing solutions.
Previous Experience in Genetic Testing Sales
Prior to his current role, Christopher Zerwas held several positions at GeneDx, where he worked from 2008 to 2018. His roles included Business Development Manager - Genetics, Regional Sales Manager, and Director of Sales for Cardiology and Neurology. During his tenure, he contributed to the promotion of advanced genetic testing methods and the integration of genomic insights into clinical practice.
Background in Pharmaceutical Sales
Christopher Zerwas has a background in pharmaceutical sales, having worked at GlaxoSmithKline as a Senior Sales Consultant from 1999 to 2002. He also served as a Product Manager at Athena Diagnostics from 2002 to 2008. His experience in these roles has equipped him with skills in sales strategy and product management within the healthcare sector.
Educational Qualifications
Christopher Zerwas studied Marketing at Pacific University, where he earned a Bachelor of Arts degree from 1984 to 1987. He also attended Western New Mexico University, studying Marketing from 1982 to 1984. His educational background has provided a foundation for his career in sales and marketing within the genetic testing and healthcare industries.
Expertise in Genetic Testing Technologies
Christopher Zerwas possesses a deep understanding of proprietary algorithms used in genetic testing to identify genetic changes. He has expertise in integrating whole genome sequencing with in-silico analyses, which enhances the accuracy of genetic testing. His knowledge in these areas supports his efforts in promoting comprehensive genomic insights.